181 related articles for article (PubMed ID: 36974615)
1. Epigenetics-based diagnostic and therapeutic strategies: shifting the paradigm in prostate cancer.
Clermont PL
Epigenomics; 2023 Jan; 15(2):75-87. PubMed ID: 36974615
[TBL] [Abstract][Full Text] [Related]
2. Identification of the epigenetic reader CBX2 as a potential drug target in advanced prostate cancer.
Clermont PL; Crea F; Chiang YT; Lin D; Zhang A; Wang JZ; Parolia A; Wu R; Xue H; Wang Y; Ding J; Thu KL; Lam WL; Shah SP; Collins CC; Wang Y; Helgason CD
Clin Epigenetics; 2016; 8():16. PubMed ID: 26877821
[TBL] [Abstract][Full Text] [Related]
3. The role of genetic markers in the management of prostate cancer.
Choudhury AD; Eeles R; Freedland SJ; Isaacs WB; Pomerantz MM; Schalken JA; Tammela TL; Visakorpi T
Eur Urol; 2012 Oct; 62(4):577-87. PubMed ID: 22695242
[TBL] [Abstract][Full Text] [Related]
4. The epigenetics of prostate cancer diagnosis and prognosis: update on clinical applications.
Blute ML; Damaschke NA; Jarrard DF
Curr Opin Urol; 2015 Jan; 25(1):83-8. PubMed ID: 25405932
[TBL] [Abstract][Full Text] [Related]
5. Concepts of epigenetics in prostate cancer development.
Cooper CS; Foster CS
Br J Cancer; 2009 Jan; 100(2):240-5. PubMed ID: 19002169
[TBL] [Abstract][Full Text] [Related]
6. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia.
Dobosy JR; Roberts JL; Fu VX; Jarrard DF
J Urol; 2007 Mar; 177(3):822-31. PubMed ID: 17296351
[TBL] [Abstract][Full Text] [Related]
7. [Long non-coding RNAs in prostate cancer: An update].
Wu PG; Zhang YX
Zhonghua Nan Ke Xue; 2018 Aug; 24(8):735-739. PubMed ID: 30173435
[TBL] [Abstract][Full Text] [Related]
8. Epigenetics-related genes in prostate cancer: expression profile in prostate cancer tissues, androgen-sensitive and -insensitive cell lines.
Adler D; Lindstrot A; Ochsenfahrt J; Fuchs K; Wernert N
Int J Mol Med; 2013 Jan; 31(1):21-5. PubMed ID: 23135352
[TBL] [Abstract][Full Text] [Related]
9. The evolution of long noncoding RNA acceptance in prostate cancer initiation, progression, and its clinical utility in disease management.
Ramnarine VR; Kobelev M; Gibb EA; Nouri M; Lin D; Wang Y; Buttyan R; Davicioni E; Zoubeidi A; Collins CC
Eur Urol; 2019 Nov; 76(5):546-559. PubMed ID: 31445843
[TBL] [Abstract][Full Text] [Related]
10. Clinical prospects of long noncoding RNAs as novel biomarkers and therapeutic targets in prostate cancer.
Mouraviev V; Lee B; Patel V; Albala D; Johansen TE; Partin A; Ross A; Perera RJ
Prostate Cancer Prostatic Dis; 2016 Mar; 19(1):14-20. PubMed ID: 26503110
[TBL] [Abstract][Full Text] [Related]
11. Lipid Metabolism and Epigenetics Crosstalk in Prostate Cancer.
Pardo JC; Ruiz de Porras V; Gil J; Font A; Puig-Domingo M; Jordà M
Nutrients; 2022 Feb; 14(4):. PubMed ID: 35215499
[TBL] [Abstract][Full Text] [Related]
12. Role of lncRNAs in prostate cancer development and progression.
Weiss M; Plass C; Gerhauser C
Biol Chem; 2014 Nov; 395(11):1275-90. PubMed ID: 25153594
[TBL] [Abstract][Full Text] [Related]
13. Recent Advances in Epigenetic Biomarkers and Epigenetic Targeting in Prostate Cancer.
Kumaraswamy A; Welker Leng KR; Westbrook TC; Yates JA; Zhao SG; Evans CP; Feng FY; Morgan TM; Alumkal JJ
Eur Urol; 2021 Jul; 80(1):71-81. PubMed ID: 33785255
[TBL] [Abstract][Full Text] [Related]
14. Epigenetic biomarkers in prostate cancer: Current and future uses.
Chiam K; Ricciardelli C; Bianco-Miotto T
Cancer Lett; 2014 Jan; 342(2):248-56. PubMed ID: 22391123
[TBL] [Abstract][Full Text] [Related]
15. Epigenetics in prostate cancer: biologic and clinical relevance.
Jerónimo C; Bastian PJ; Bjartell A; Carbone GM; Catto JW; Clark SJ; Henrique R; Nelson WG; Shariat SF
Eur Urol; 2011 Oct; 60(4):753-66. PubMed ID: 21719191
[TBL] [Abstract][Full Text] [Related]
16. Involvement of aberrantly activated HOTAIR/EZH2/miR-193a feedback loop in progression of prostate cancer.
Ling Z; Wang X; Tao T; Zhang L; Guan H; You Z; Lu K; Zhang G; Chen S; Wu J; Qian J; Liu H; Xu B; Chen M
J Exp Clin Cancer Res; 2017 Nov; 36(1):159. PubMed ID: 29141691
[TBL] [Abstract][Full Text] [Related]
17. Epigenetic targets in the diagnosis and treatment of prostate cancer.
Manoharan M; Ramachandran K; Soloway MS; Singal R
Int Braz J Urol; 2007; 33(1):11-8. PubMed ID: 17335593
[TBL] [Abstract][Full Text] [Related]
18. Known epigenetic biomarkers for prostate cancer detection and management: exploring the potential of blood-based liquid biopsies.
Constâncio V; Barros-Silva D; Jerónimo C; Henrique R
Expert Rev Mol Diagn; 2019 May; 19(5):367-375. PubMed ID: 30961397
[TBL] [Abstract][Full Text] [Related]
19. Polycomb-mediated silencing in neuroendocrine prostate cancer.
Clermont PL; Lin D; Crea F; Wu R; Xue H; Wang Y; Thu KL; Lam WL; Collins CC; Wang Y; Helgason CD
Clin Epigenetics; 2015; 7(1):40. PubMed ID: 25859291
[TBL] [Abstract][Full Text] [Related]
20. Functions and mechanisms of N6‑methyladenosine in prostate cancer (Review).
Wan H; Feng Y; Wu J; Zhu L; Mi Y
Mol Med Rep; 2022 Sep; 26(3):. PubMed ID: 35856412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
